UTHR 📈 United Therapeutics - Overview

United Therapeutics Corporation is a biotechnology company that focuses on developing and commercializing innovative products to address the unmet medical needs of patients with chronic and life-threatening diseases. The company's product portfolio includes Tyvaso DPI, an inhaled dry powder formulation, and Tyvaso, an inhaled solution, both of which are used to treat pulmonary arterial hypertension (PAH). Additionally, the company offers Remodulin, a treprostinil injection, and Orenitram, a tablet dosage form of treprostinil, to treat PAH and improve exercise capacity in patients. Adcirca, an oral PDE-5 inhibitor, is also part of the company's product lineup, aimed at enhancing exercise ability in PAH patients.

The company's product offerings extend to Unituxin, a monoclonal antibody for treating high-risk neuroblastoma, and the Remunity Pump, a system that includes a pump and separate controller for Remodulin administration. United Therapeutics Corporation is also invested in developing new treatments, such as RemoPro and Ralinepag for PAH, as well as Aurora-GT, a gene therapy product designed to rebuild blood vessels in the lungs. Furthermore, the company is working on Nebulized Tyvaso for the treatment of idiopathic pulmonary fibrosis and is exploring the development of xenografts, which are development-stage organ products.

Through strategic partnerships, United Therapeutics Corporation has established licensing and collaboration agreements with various companies, including DEKA Research & Development Corp., MannKind Corporation, and Arena Pharmaceuticals, Inc. These collaborations aim to advance the development of innovative products, such as a semi-disposable system for the subcutaneous delivery of treprostinil and a treprostinil inhalation powder. With a strong foundation in research and development, the company continues to expand its product pipeline and improve treatment options for patients with chronic and life-threatening diseases. Incorporated in 1996, United Therapeutics Corporation is headquartered in Silver Spring, Maryland, and its common stock is listed on the NASDAQ under the ticker symbol UTHR.

As a leading biotechnology company, United Therapeutics Corporation operates with a focus on innovation and patient-centricity. With a robust product portfolio and a strong pipeline of development-stage products, the company is well-positioned to address the complex medical needs of patients worldwide. Through its commitment to research and development, strategic partnerships, and dedication to improving patient outcomes, United Therapeutics Corporation continues to make significant contributions to the biotechnology industry. For more information, please visit the company's website at https://www.unither.com, or review its financial and operational details, including its ISIN (US91307C1027) and GICS Sub Industry classification as a biotechnology company.